Gene editing has emerged as a powerful approach for targeting the genetic causes of disease, but getting the editing machinery into the right cells efficiently, safely, and at the scale needed for therapies remains one of the biggest set of challenges in the field.

Among the leading delivery vehicles are engineered virus-like particles, which resemble viruses—and share their knack for entering human cells—but carry no viral genes. Scientists load them with gene editing tools and use them to make precise changes in targeted cells.

Most efforts to improve these particles have focused on redesigning the particles themselves. A new study led by Valhalla Fellow at Whitehead Institute, Aditya Raguram and lab technician Diana Ly, focuses instead on the human cells that produce them.